Overview
The study is a prospective two-arm, open-label, interventional study with four treatment procedures and two follow-up visits.
Description
This study aims to evaluate the clinical safety and efficacy of the BTL-899 device for non-invasive lipolysis and fat reduction in the thigh and saddlebag area. This is a prospective, open-label, two-arm study; therefore the participants will be assigned to two study groups. Each participant will complete 4 treatment visits and 2 follow-up visits.
Eligibility
Inclusion Criteria:
- Body Mass Index (BMI) of 20 to 35 kg/m2.
- Visible excess of adipose tissue at the treatment sites (ARM 1 - thigh area; ARM 2 - saddlebags area).
- Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
- No procedure for fat reduction (including cellulite treatment) in the last six months.
- Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during study participation.
- Age between 21 and 70 years.
Exclusion Criteria:
- Electronic implants (such as intrauterine device, cardiac pacemakers, defibrillators, and neurostimulators)
- Cardiovascular diseases
- Vascular diseases (such as chronic venous insufficiency, deep venous thrombosis, varicose veins, etc.)
- Femoral or inguinal hernia
- Disturbance of temperature or pain perception
- Pulmonary insufficiency
- Metal implants
- Drug pumps
- Malignant tumor
- Hemorrhagic conditions
- Septic conditions and empyema
- Acute inflammations
- Systemic or local infection such as osteomyelitis and tuberculosis
- Contagious skin disease
- Elevated body temperature
- Pregnancy
- Breastfeeding
- Injured or otherwise impaired muscles
- Scars, open lesions, and wounds at the treatment area
- Basedow's disease
- Previous liposuction in the treatment area in the last six months
- Unstable weight within the last 6 months (change in weight 3%)
- Previous body contouring or cellulite treatments in the thighs area in the last six months
- Any other disease or condition at the investigator's discretion